Karl W Oestreich (@KarlWOestreich)
Activity by Karl W Oestreich
ROCHESTER, Minn. – The City of Rochester today announced the proposed acquisition of the historic Chateau Theatre located in Peace Plaza in downtown Rochester. The city will discuss executing a purchase agreement for the 88-year-old theatre at its April 6 City Council meeting.
“This a tremendous opportunity for us to preserve this iconic element of Rochester’s history and invest in our future,” said Mayor Ardell Brede, “Thanks to the generosity of Mayo Clinic, we are now able to meet the purchase price of six-million dollars.”
Journalists: Sound bites and b-roll from the event are in the downloads.
ROCHESTER, Minn. — Mayo Clinic reports a strong 2014 performance, including providing direct care for more than 1.3 million people, contributions of $410 million to its pension plan as a commitment to employees, and plans for a $1.5 billion investment to fund information technology infrastructure.
“Whether viewed through the lens of quality, patient outcomes, research advances, operational performance or sharing our knowledge with the world — by all measures, we had an extraordinary year,” says John Noseworthy, M.D., president and CEO, Mayo Clinic. “That success allowed us to reinvest in our people, our infrastructure and our mission so we can better serve our patients.”
“As a nonprofit organization, it’s important for us to not only reinvest in our technology infrastructure, but also invest in our employees,” says Jeff Bolton, vice president, administration, Mayo Clinic. To that end, Mayo Clinic made an additional contribution of $190 million to its pension fund, bringing the total 2014 contribution to $410 million. This additional investment was necessary to ensure Mayo Clinic will meet its commitment to current and future retirees.
“Our financial performance gives us the flexibility to invest in new initiatives that will help our patients,” says Kedrick Adkins Jr., Mayo chief financial officer. These funds are committed to mission-advancing projects. The funding includes five areas of focus, Adkins says:
PHOENIX — The Mayo Clinic Board of Trustees welcomed Gianrico Farrugia, M.D. ,as a new member, re-elected two internal trustees and one public trustee, and also recognized three recipients of Mayo Clinic named professorships at its board meeting today.
Dr. Farrugia was named Mayo Clinic vice president and chief executive officer (CEO) of Mayo Clinic's campus in Jacksonville, Florida, in August 2014. He replaces William Rupp, M.D., who retired at the end of 2014 and was elected as an emeritus trustee. Michael Powell, who joined the board in 2011, was re-elected as a public trustee. Powell, who is president and CEO of the National Cable & Telecommunications Association (NCTA), was chairman of the Federal Communications Commission (FCC) from 2001 to 2005 and a member of the FCC for eight years.
The board re-elected two internal trustees:
The Mayo Clinic Board of Trustees also recognized three new named professorships, the highest academic distinction for faculty members at Mayo Clinic. [...]
ROCHESTER, Minn -- Acting Director of the Mayo Clinic Center for Individualized Medicine, Richard Weinshilboum M.D., says, "We are pleased and heartened that President Obama plans to increase federal funding for precision or individualized medicine, which Mayo Clinic views as integral to the future of health care. We eagerly await more details of the initiative and look forward to contributing however we can. The Mayo Clinic Center for Individualized Medicine has been a leader in this field for many years and opened the world's first integrated, multidisciplinary Individualized Medicine Clinic for patients with rare or undiagnosed diseases and patients with cancers."
For more information about the Mayo Clinic Center For Individualized Medicine: http://mayoresearch.mayo.edu/center-for-individualized-medicine/
MEDIA: To interview Dr. Weinshilboum contact Sam Smith or Karl Oestreich, Mayo Clinic Public Affairs, 507-284-5005, email@example.com.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.
ROCHESTER, Minn., — Mayo Clinic announced today that Epic has been selected as its strategic partner for a single, integrated electronic health record (EHR) and revenue cycle management (RCM) system. The new system will replace Mayo’s three EHRs in use today and will be a foundation for Mayo Clinic operations over the next several decades.
“We’re confident in choosing Epic as our strategic partner as we continue to enhance Mayo Clinic’s excellence in health care and medical innovation,” says John Noseworthy, M.D., Mayo Clinic president and CEO. [...]
JACKSONVILLE, Fla. — The Mayo Clinic Board of Trustees welcomed Mary Sue Coleman, Ph.D., as a new public member at its quarterly meeting today.
Dr. Coleman is president emeritus of the University of Michigan, (U-M) an institution she led for 12 years before retiring in July 2014. Time magazine named her one of the nation’s “10 best college presidents,” and the American Council on Education honored her with its Lifetime Achievement Award. She previously was president of the University of Iowa.
As University of Michigan president, Dr. Coleman unveiled several major initiatives designed to impact on future generations of students, the intellectual life of the campus, and society at large. The initiatives focused on the interdisciplinary richness of the U-M, student residential life, the economic vitality of the state and nation, global engagement and the value of innovation and creativity. President Obama chose Dr. Coleman to help launch the Advanced Manufacturing Partnership, a national effort bringing together industry, universities and the federal government.
Click here for a bio of Dr. Mary Sue Coleman.
MEDIA CONTACT: Karl Oestreich, Mayo Clinic Public Affairs, 507-284-5005, firstname.lastname@example.org.
Board Also Recognizes Four Recipients of Mayo Clinic Named Professorships
JACKSONVILLE, Fla., and ROCHESTER, Minn. — The Mayo Clinic Board of Trustees has named Gianrico Farrugia, M.D., Mayo Clinic vice president and chief executive officer of Mayo Clinic's campus in Jacksonville, Florida. Dr. Farrugia succeeds William Rupp, M.D., who will retire from Mayo Clinic at the end of 2014. The announcement was made today at the Mayo Clinic Board of Trustees quarterly meeting where the board also recognized four recipients of Mayo Clinic named professorships.
Soundbites of Dr. Noseworthy are available in the downloads box.
“Dr. Farrugia brings a wealth of experience to his new role,” says John Noseworthy, M.D., Mayo Clinic president and chief executive officer. “He is a physician-leader who brings to this important role a deep commitment to Mayo’s values, mission and strategic vision, along with a passion to lead and equip teams to reach more patients and strengthen Mayo Clinic’s position as a global health care leader. He has a strong commitment to continuing Dr. Rupp’s legacy of involvement and leadership in the Jacksonville community.”
Dr. Farrugia has been with Mayo Clinic for more than 26 years as a physician in the Division of Gastroenterology and Hepatology and Division of Physiology and Biomedical Engineering at Mayo Clinic’s campus in Rochester, Minnesota. He is also a professor of medicine as well as physiology and biomedical engineering. Dr. Farrugia has served in numerous leadership roles at Mayo Clinic with multisite responsibilities, both in his specialty and at the organizational leadership level. He currently serves as director of the Mayo Clinic Center for Individualized Medicine and director of Mayo Clinic’s Enteric Neuroscience Program. He previously served as research chair of the Department of Medicine.
In his new role, Dr. Farrugia will work with Bob Brigham, chief administrative officer in Florida, to provide leadership and direction, defining and implementing Mayo Clinic’s operational plan and continuing to expand Mayo Clinic’s leadership and reach in the Southeast and beyond.
ROCHESTER, Minn. — The Mayo Clinic Board of Trustees recognized four new named professorships, the highest academic distinction for faculty members at Mayo Clinic, during its quarterly meeting today.
Michael Brodsky, M.D., a physician with joint appointments in the Department of Neurology and Department of Ophthalmology, is recognized as the Knights Templar Eye Foundation, Inc. Professor in Ophthalmology Research. The Knights Templar Eye Foundation, incorporated in 1956, is a charity sponsored by the Grand Encampment of Knights Templar. The organization’s mission is to improve vision through research and education and by supporting access to care.
As a researcher, Dr. Brodsky focuses on evolutionary mechanisms of infantile strabismus (a condition in which the eyes are not properly aligned with one another); congenital optic disc anomalies; ocular motor physiology; nystagmus (a condition of involuntary eye movement acquired in infancy or later in life, that may result in reduced or limited vision); and other ocular motility disturbances. He has authored or co-authored several textbooks, including the definitive Pediatric Neuro-Ophthalmology.
He has also established a video-oculography laboratory at Mayo Clinic to study the role of binocular luminance disparity in infantile strabismus.
Douglas Husmann, M.D., Department of Urology, is recognized as the Anson L. Clark Professor in Urology. This professorship was established in 1974 by The Clark Foundation of Dallas, Texas, in memory of Anson L. Clark, M.D. Dr. Clark was a member of the Mayo Clinic staff in the section of special urology and an instructor in urology from 1931 to 1934.
As a urologist, Dr. Husmann’s clinical and research focus includes pediatric and reconstructive urology, and he has extensive experience in urologic reconstructive surgical procedures in both congenital abnormalities and traumatic injuries. He excels at translating basic science findings to the clinical arena. His work has resulted in numerous advances in the fields of androgen receptor physiology, the management of reproductive congenital abnormalities, traumatic genitourinary injuries and reconstructive urology.